Skip to main content

Drug-Drug Interaction

6
Pipeline Programs
7
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
Dihydroartemisinin-piperaquinePhase 41 trial
Active Trials
NCT04487145Completed194Est. Apr 2022
Otsuka
OtsukaJapan - Tokushima
1 program
1
AVP-786Phase 15 trials
Active Trials
NCT02402595Completed24Est. Jul 2015
NCT02336347Completed62Est. Mar 2015
NCT02174822Completed56Est. Apr 2014
+2 more trials
Quotient Therapeutics
Quotient TherapeuticsMA - Cambridge
1 program
1
BelumosudilPhase 11 trial
Active Trials
NCT03530995Completed73Est. Feb 2019
Lexicon Pharmaceuticals
Lexicon PharmaceuticalsNJ - Bridgewater
1 program
1
Omeprazole 40 MGPhase 11 trial
Active Trials
NCT03302845Completed32Est. Nov 2017
Santhera Pharmaceuticals
Santhera PharmaceuticalsSwitzerland - Pratteln
1 program
1
RaxonePhase 11 trial
Active Trials
NCT02887443Completed32Est. Nov 2016
Genfit
GenfitFrance - Loos
1 program
1
elafibranorPhase 11 trial
Active Trials
NCT03985969Completed26Est. Mar 2020
Biosplice Therapeutics
1 program
LorecivivintPHASE_11 trial
Active Trials
NCT04598542Completed40Est. Dec 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Human BioSciencesDihydroartemisinin-piperaquine
Biosplice TherapeuticsLorecivivint
Genfitelafibranor
Quotient TherapeuticsBelumosudil
Lexicon PharmaceuticalsOmeprazole 40 MG
Santhera PharmaceuticalsRaxone
OtsukaAVP-786
OtsukaAVP-786
OtsukaAVP-786
OtsukaAVP-786
OtsukaAVP-786

Clinical Trials (11)

Total enrollment: 643 patients across 11 trials

NCT04487145Human BioSciencesDihydroartemisinin-piperaquine

Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy

Start: Nov 2020Est. completion: Apr 2022194 patients
Phase 4Completed

Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers

Start: Oct 2020Est. completion: Dec 202040 patients
Phase 1Completed

Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin

Start: Sep 2019Est. completion: Mar 202026 patients
Phase 1Completed

Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

Start: Apr 2018Est. completion: Feb 201973 patients
Phase 1Completed

A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects

Start: Sep 2017Est. completion: Nov 201732 patients
Phase 1Completed

A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate

Start: Sep 2016Est. completion: Nov 201632 patients
Phase 1Completed

Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts

Start: Mar 2015Est. completion: Jul 201524 patients
Phase 1Completed

A Phase 1 Study Comparing AVP-786 With AVP-923

Start: May 2014Est. completion: Mar 201562 patients
Phase 1Completed

A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects

Start: Jan 2014Est. completion: Apr 201456 patients
Phase 1Completed

A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers

Start: Sep 2013Est. completion: Nov 201356 patients
Phase 1Completed

Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers

Start: Oct 2012Est. completion: Feb 201348 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.